Ranbaxy says settles dispute with Takeda Pharma
MUMBAI, March 15 |
MUMBAI, March 15 (Reuters) - India's Ranbaxy Laboratories (RANB.BO) has settled litigation with Japan's Takeda Pharmaceutical (4502.T) over a generic equivalent version of anti-diabetic drug Actos.
Takeda has granted Ranbaxy a non-exclusive royalty free license for its U.S. patents covering Actos, Ranbaxy, which is majority owned by Daiichi Sankyo (4568.T), said in a statement on Monday. (Reporting by Ketan Bondre)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters